Westlake Corporation
WLK
$61.52
-2.95%
Westlake Corporation is a Houston-based, forward-integrated commodity chemicals manufacturer whose core operations span ethylene, polyethylene, vinyl chloride monomers, polyvinyl chloride (PVC), and chlor-alkali production, complemented by a growing Housing and Infrastructure Products (HIP) segment that converts its chemical output into higher-margin finished building goods such as pipe, fittings, and trim. As North America's leading chlor-alkali and PVC producer following the transformative 2016 Axiall acquisition, Westlake occupies a scale-driven, cost-advantaged position in a capital-intensive industry where integration and feedstock advantage (shale-advantaged ethane) are the primary competitive moats. The current investor narrative is dominated by a severe cyclical downturn: the company reported a Q1 2026 net loss of $169 million before swinging to $260 million of net income in Q2, announced the closure of its Cologne PVC plant amid a structurally weak European market, and is contending with negative free cash flow and a stock that has fallen sharply over the past year. Debate centers on whether this is a deep cyclical trough offering contrarian value at roughly 1.1x book, or evidence of structural margin erosion in commodity chemicals that warrants a sustained de-rating.…
WLK
Westlake Corporation
$61.52
Investment Opinion: Should I buy WLK Today?
Based on the synthesis of data, Westlake Corporation (WLK) warrants a Hold rating. The core thesis is that the company is in a deep cyclical trough with potential for recovery, but significant risks remain, including negative free cash flow and structural challenges in Europe. The analyst consensus rating is 'buy' with an average target price of $87.375, implying 37.6% upside, but the recent downgrade by BMO and predominance of neutral ratings suggest caution.
Supporting evidence for a Hold includes the deeply depressed valuation at 0.853x PS and 1.084x P/B, well below historical ranges, which could attract value investors. Revenue grew 10.77% year-over-year in Q2 2026 to $3.271 billion, and net income swung to $260 million from a loss, indicating a potential inflection. However, trailing free cash flow is -$265 million, and the debt-to-equity ratio of 0.729 is high, limiting financial flexibility. The dividend yield of 2.85% is above historical averages but may not be sustainable if cash burn continues.
The biggest risks that could invalidate the thesis include a failure of the cyclical recovery, further deterioration in European markets, and a dividend cut. The rating would upgrade to Buy if free cash flow turns positive and gross margins sustain above 20%, or downgrade to Sell if revenue growth decelerates below 5% or the company cuts its dividend. Relative to its history and peers, WLK appears undervalued on asset-based metrics but fairly valued on forward earnings, suggesting a balanced risk-reward profile.
Sign up to view all
WLK 12-Month Price Forecast
Westlake presents a high-risk, potentially high-reward contrarian opportunity. The company has shown a significant earnings inflection in Q2 2026, but negative free cash flow and high debt remain concerns. The valuation is deeply depressed on asset-based metrics, but forward earnings multiples are not cheap, implying the market expects a strong recovery. Analyst sentiment is mixed, with a consensus buy rating but a wide target range and recent downgrades. I would upgrade to bullish if free cash flow turns positive and gross margins sustain above 20%, and downgrade to bearish if the recovery stalls or liquidity deteriorates further.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Westlake Corporation's 12-month outlook, with a consensus price target around $85.63 and implied upside of +39.2% versus the current price.
Average Target
$85.63
0 analysts
Implied Upside
+39.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$67 - $114
Analyst target range
Westlake is covered by 16 analysts with a consensus recommendation of "buy" (recommendation mean of 2.375 on a scale where lower is more bullish), and an average price target of $87.375. Against the current price of $63.50, this implies approximately +37.6% upside to the consensus target — a wide gap that reflects analysts' belief that the stock is significantly oversold relative to fundamental fair value. However, the sentiment is more nuanced than the headline "buy" suggests: the institutional ratings show a clear skew toward neutral/hold actions, with recent moves including BMO Capital downgrading to Market Perform from Outperform on September 9, 2026, and firms like Wells Fargo, Morgan Stanley, Mizuho, BofA, and Citigroup all maintaining Equal Weight or Neutral ratings, while only UBS and Truist maintain outright Buy ratings.
The target range spans from a low of $67.00 to a high of $114.00, a spread of $47.00, or roughly 70% of the average target — signaling substantial disagreement about the company's trajectory. The low target of $67.00 implies only +5.5% upside and likely assumes continued margin compression, European restructuring costs, and a delayed cyclical recovery. The high target of $114.00 implies +79.5% upside and likely prices in a full mid-cycle earnings recovery, successful cost actions from the Cologne closure, and a rebound in PVC and caustic soda pricing. The consensus estimated EPS of $3.55 (range $2.53 to $4.63) and estimated revenue of $12.51 billion (range $11.68 billion to $14.31 billion) show similarly wide dispersion. The recent downgrade by BMO and the preponderance of neutral ratings suggest analysts are increasingly cautious despite the headline buy consensus, and the wide target spread — combined with the stock trading near 52-week lows — indicates high uncertainty and limited conviction, which typically portends continued volatility.
Drowning in data?
Find the real signal!
Bulls vs Bears: WLK Investment Factors
The bear case currently has stronger evidence due to the relentless downtrend, negative free cash flow, and structural challenges in Europe. However, the bull case rests on a tangible Q2 2026 earnings inflection and deeply depressed valuation multiples that historically preceded mean reversion. The single most important tension is whether the Q2 2026 profitability recovery is the start of a sustainable cyclical upturn or merely a dead-cat bounce; if it is the former, the stock is dramatically undervalued, but if it is the latter, the low multiples are a value trap. Analyst sentiment is mixed, with a consensus 'buy' rating but a wide target range and recent downgrades, reflecting high uncertainty. Ultimately, the resolution of this tension will determine whether WLK is a contrarian opportunity or a falling knife.
Bullish
- Deep value on sales and book: WLK trades at 0.853x trailing PS and 1.084x price-to-book, below the bottom of its 2022-2024 valuation bands of 2.81x-6.66x PS and 1.16x-1.92x P/B. This extreme compression suggests the market is pricing in a permanent impairment that may not materialize if the Q2 2026 profitability recovery proves durable.
- Q2 2026 earnings inflection: After a Q1 2026 net loss of $169 million, Westlake swung to $260 million of net income in Q2 2026, with gross margin recovering to 19.93% and operating margin to 11.13%. Revenue also grew 10.77% year-over-year to $3.271 billion, indicating the cyclical trough may have passed.
- Analyst consensus upside: The 16-analyst consensus average target price of $87.375 implies 37.6% upside from the current $63.50, with a high target of $114.00 (79.5% upside). Even the low target of $67.00 represents 5.5% upside, suggesting analysts see limited downside from here.
- Defensive low beta: WLK's beta of 0.629 means it is roughly 37% less volatile than the broader market, which is unusual for a commodity chemicals firm. This defensive characteristic could attract income and value investors seeking lower volatility exposure to a cyclical recovery.
Bearish
- Severe downtrend and relative weakness: WLK has fallen 46.82% over six months and 20.50% over one year, massively underperforming the S&P 500's +17.35% and +15.01% respective returns. The relative strength versus the S&P 500 is -64.17% over six months, indicating company-specific capitulation rather than a market-wide selloff.
- Negative free cash flow and cash burn: Trailing twelve-month free cash flow is -$265 million, and cash fell from $2.74 billion at year-end 2025 to $1.66 billion by Q2 2026. With capital expenditures of $207-209 million per quarter and dividends of $69 million per quarter, the company is burning through reserves, raising questions about dividend sustainability.
- Elevated debt and poor returns: The debt-to-equity ratio of 0.729 and total debt-to-capitalization of 39.77% are high for a cyclical chemicals firm. ROE is -17.15% and ROA is just 0.37%, indicating returns far below the cost of capital and limited financial flexibility.
- Structural European weakness: The announced closure of the Cologne PVC plant underscores a structural downturn in European commodity chemicals, with the company citing a weak market. This suggests the recovery may be uneven and that further restructuring charges could weigh on earnings.
WLK Technical Analysis
Westlake is in a pronounced, sustained downtrend across every measurable horizon. The stock's 1-year price change of -20.50% masks a far more severe 6-month decline of -46.82%, and at $63.50 the shares sit just 11.4% above their 52-week low of $56.33 and 48.9% below their 52-week high of $124.23 — positioning the stock in the bottom quartile of its annual range, which typically signals either deep-value territory or a falling knife still in motion. The magnitude of the drawdown (max drawdown of -49.5%) confirms this is a violent de-rating rather than a garden-variety pullback, and the burden of proof rests on the bulls to demonstrate a fundamental inflection before the trend can be called exhausted.
Short-term momentum is unambiguously negative and deteriorating. The 1-month change of -16.74% is worse than the 3-month change of -15.07%, meaning the pace of decline has accelerated in recent weeks rather than stabilized, and the 6-month figure of -46.82% shows the selling has been relentless rather than episodic. Relative strength versus the S&P 500 is deeply negative across all windows — -17.33% over 1 month, -18.41% over 3 months, and a staggering -64.17% over 6 months — indicating this is not a market-wide risk-off event but a company- and sector-specific capitulation. The lone bright spot is the most recent session's +1.65% bounce off the $62.31 close, but a single up-day after a -16.7% monthly collapse is noise, not a reversal signal.
Key technical levels are clearly defined by the 52-week range. Support rests at the $56.33 52-week low, roughly 11.3% below the current $63.50 price; a breakdown below that level would open the door to new multi-year lows and likely trigger further momentum-driven selling. Resistance is anchored at the $124.23 52-week high, but the more relevant near-term resistance is the $70–$80 zone where the stock repeatedly failed in August and September 2026. Notably, the beta of 0.629 means Westlake is roughly 37% less volatile than the broader market — a defensive characteristic that makes the -46.82% six-month decline all the more striking, since it reflects company-specific deterioration rather than high-beta amplification. For risk management, the low beta argues for smaller-than-typical position sizing adjustments, but the -49.5% max drawdown demonstrates that low beta offers little protection against idiosyncratic commodity-cycle risk.
Beta
0.69
0.69x market volatility
Max Drawdown
-50.1%
Largest decline past year
52-Week Range
$56-$124
Price range past year
Annual Return
-23.4%
Cumulative gain past year
| Period | WLK Return | S&P 500 |
|---|---|---|
| 1m | -17.7% | +0.9% |
| 3m | -17.4% | +3.4% |
| 6m | -48.0% | +14.4% |
| 1y | -23.4% | +16.2% |
| ytd | -17.0% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WLK Fundamental Analysis
Westlake's revenue trajectory has been erratic and is only now showing tentative stabilization. Q2 2026 revenue of $3.271 billion grew 10.77% year-over-year against Q2 2025's $2.953 billion, and rose sequentially from Q1 2026's $2.652 billion, but the multi-quarter pattern is choppy: revenue fell from $2.953 billion in Q2 2025 to $2.838 billion in Q3 2025 and $2.533 billion in Q4 2025 before recovering. Segment data shows the Performance and Essential Materials segment at $2.019 billion and Housing and Infrastructure Products at $1.252 billion, meaning the commodity chemicals business still drives roughly 62% of revenue and remains the primary swing factor in the growth story. The 10.77% YoY growth is encouraging, but it comes off a depressed base and against a backdrop of European plant closures, suggesting the recovery is volume- and price-cyclical rather than structural.
Profitability has swung violently between loss and profit, reflecting the extreme operating leverage inherent in commodity chemicals. Q2 2026 delivered net income of $260 million on a gross margin of 19.93% and an operating margin of 11.13%, a dramatic reversal from Q1 2026's net loss of $169 million on a 3.09% gross margin and Q4 2025's catastrophic $544 million loss on a negative 17.25% gross margin. The trailing figures remain deeply negative — net margin of -13.50%, operating margin of -14.13%, and gross margin of just 2.59% — because the trailing twelve months still absorb the Q3 2025 (-$782 million) and Q4 2025 (-$544 million) losses. The Q2 2026 gross margin of 19.93% is a meaningful recovery but remains below the ~20-32% range the company posted in 2022-2024, indicating that while the worst may be past, margins have not normalized to mid-cycle levels.
Balance sheet and cash flow metrics reveal a company under real financial strain despite adequate liquidity. Free cash flow on a trailing twelve-month basis is -$265 million, and Q1 2026 free cash flow was -$303 million before improving to +$111 million in Q2 2026, showing the company is only marginally self-funding. The debt-to-equity ratio of 0.729 and total debt-to-capitalization of 39.77% are elevated for a cyclical chemicals firm, and with ROE at -17.15% and ROA at just 0.37%, returns on capital are far below the cost of capital. The current ratio of 2.244 and cash balance of $1.66 billion provide a solid liquidity cushion, but with capital expenditures running at $207-209 million per quarter and dividends of $69 million per quarter, the company is burning through cash reserves — cash fell from $2.74 billion at year-end 2025 to $1.66 billion by Q2 2026 — which raises questions about the sustainability of the current dividend and buyback program if the cyclical recovery stalls.
Quarterly Revenue
$3.3B
2026-06
Revenue YoY Growth
+10.8%
YoY Comparison
Gross Margin
19.9%
Latest Quarter
Free Cash Flow
$-265000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WLK Overvalued?
Because Westlake's trailing net income is negative (EPS of -$0.158, trailing PE of -6.30x), the PE ratio is not meaningful and I have selected the price-to-sales (PS) ratio as the primary valuation metric, supplemented by the forward PE. The trailing PS ratio of 0.853x is exceptionally low in absolute terms, and the forward PE of 21.42x — based on consensus estimated EPS of $3.55 — implies the market expects a full earnings recovery, since a 21.4x forward multiple on trough earnings is not cheap if those estimates prove optimistic. The enormous gap between the negative trailing PE and the positive 21.4x forward PE captures the entire bull-bear debate: the market is pricing in a sharp cyclical rebound that has not yet been confirmed by reported results.
Relative to the broader Basic Materials/Chemicals sector, Westlake's 0.853x PS ratio and 1.084x price-to-book ratio screen as deep-value outliers, though the comparison is complicated by the sector's own cyclical trough. The EV/Sales of 1.108x and EV/EBITDA of -66.42x (negative due to trailing EBITDA losses) further illustrate that on asset-based and revenue-based measures the stock is inexpensive, but the PCF ratio of 20.50x and price-to-free-cash-flow of 84.21x show that cash-flow-based metrics are stretched because cash generation has collapsed. The dividend yield of 2.85% is above the stock's own historical average (which ranged from 0.25% to 0.74% in 2022-2024), a direct consequence of the price decline rather than a dividend increase — a classic sign of a beaten-down cyclical.
Historical context is critical here: Westlake's PS ratio ranged from 2.81x to 6.66x during 2022-2024, and its price-to-book ranged from 1.16x to 1.92x over the same period. At 0.853x PS and 1.084x P/B, the stock is trading at or below the very bottom of its multi-year valuation band — cheaper than at any point in the past four years. This extreme compression suggests the market is pricing in either a prolonged trough or permanent impairment of earning power. If the Q2 2026 profitability recovery proves durable, the current valuation offers substantial mean-reversion potential; if it proves a dead-cat bounce, the low multiples are a value trap, and the negative free cash flow and 39.77% debt-to-capitalization provide little margin for error.
PE
-6.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 4x~15x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-66.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. Westlake's trailing twelve-month free cash flow is -$265 million, and cash reserves have declined from $2.74 billion at year-end 2025 to $1.66 billion by Q2 2026, partly due to capital expenditures of $207-209 million per quarter and $69 million in quarterly dividends. The debt-to-equity ratio of 0.729 and total debt-to-capitalization of 39.77% are elevated for a cyclical chemicals firm, and with ROE at -17.15% and ROA at 0.37%, returns are well below the cost of capital. The company's profitability is highly volatile, swinging from a $544 million loss in Q4 2025 to $260 million net income in Q2 2026, reflecting extreme operating leverage and dependence on commodity price cycles.
Market and competitive risks are pronounced. The stock is in a severe downtrend, with a 6-month decline of 46.82% and relative strength versus the S&P 500 of -64.17%, indicating company-specific issues rather than broad market weakness. The closure of the Cologne PVC plant highlights structural challenges in European commodity chemicals, and competitors may be better positioned. The forward PE of 21.42x on estimated EPS of $3.55 is not cheap if earnings disappoint, and the wide analyst target range ($67-$114) signals low conviction. With a beta of 0.629, the stock is less volatile than the market, but the -49.5% max drawdown shows it is not immune to idiosyncratic risk.
In a worst-case scenario, a prolonged cyclical downturn or failure of the Q2 2026 recovery could push the stock below its 52-week low of $56.33, representing a 11.3% decline from the current $63.50. If analyst bear-case targets are met, the low target of $67.00 implies only 5.5% upside, but a breakdown could lead to new multi-year lows. From the current price, a drop to the 52-week low would result in a loss of approximately 11.3%, and if the stock revisits its 2024 lows, the downside could be more severe. The negative free cash flow and high debt provide little margin for error, and a dividend cut could trigger further selling.
FAQ
The key risks include financial risks such as negative free cash flow and high debt (D/E of 0.729), which could lead to a dividend cut. Operational risks include structural weakness in European chemicals and volatile margins. Market risks include a high short ratio of 7.41 and a severe downtrend, with the stock down 46.82% over six months. Company-specific risks include the success of the Cologne closure and dependence on cyclical demand.
The 12-month forecast is uncertain, with a base case (50% probability) targeting $67-$87.375, a bull case (25%) targeting $87.375-$114, and a bear case (25%) targeting $56.33-$67. The base case assumes gradual recovery, while the bull case requires a strong cyclical upturn. The most likely scenario is the base case, with the key assumption that Q2 2026 profitability is sustainable but not robust.
WLK appears undervalued on asset-based metrics, with PS and P/B ratios at multi-year lows. However, the forward PE of 21.42x on estimated EPS of $3.55 is not cheap, suggesting the market expects a strong earnings recovery. Relative to its own history, the stock is cheap, but relative to current earnings, it is fairly valued. The valuation implies the market is pricing in a successful turnaround, which carries execution risk.
WLK is not a straightforward buy; it is a high-risk contrarian play. The stock trades at 0.853x PS and 1.084x P/B, well below historical averages, and the analyst average target of $87.375 implies 37.6% upside. However, negative free cash flow of -$265 million and a 46.82% six-month decline highlight significant risks. It may be suitable for value investors with a long horizon who believe in a cyclical recovery, but it is not for the faint of heart.
WLK is more suitable for long-term investment, given its cyclical nature and current turnaround phase. The low beta of 0.629 suggests lower volatility, but the stock has high idiosyncratic risk. Short-term trading is risky due to the strong downtrend and potential for further declines. A minimum holding period of 2-3 years is recommended to allow for a full cyclical recovery.
